The Company is a Taiwan-based trading company mainly engaged in the immune genetic engineering and the development of non-genetically modified cell therapy products and non-cell products.
The main business focuses on immune cell therapy that uses genetic engineering to modify the patient s own immune cells. The Company is engaged in the development of chimeric antigen receptor T cell therapy for the treatment of B-cell lymphoma PL001. Non-genetically modified cell therapy products include cytokine-induced killer cells (CIK), and mixed cells using a combination of dendritic cells and cytokine-induced killer cells (DC-CIK). Non-cell products include hair care products and others.
History
The Company was established on March 30, 2017.The Company listed on Public Companies of Taiwan Stock Exchange on March 8, 2024.The Company listed on TSEC of Taiwan Stock Exchange on March 8, 2024.
Headquarters
4F.,No.87,Xinhu 2Nd Rd, Neihu Dist
Taipei City; Taipei City;
Contact Details: Purchase the Pell Bio-Med Technology Co. Ltd. report to view the information.
Website: http://www.pellbmt.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service